Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objective of this study is to evaluate whether treatment with nesiritide improves patient outcomes (as measured by reduction in the composite of HF rehospitalization and all-cause mortality through 30 days after randomization [Day 30]) or HF symptoms (as measured by subject self assessed Likert dyspnea scale at 6 hours and 24 hours after study drug initiation) compared with placebo when each is administered in addition to other standard therapies in patients with ADHF.
Inclusion criteria
- Acute decompensated heart failure